Private variants in PRKN are associated with late-onset Parkinson's disease

Funding

This study was funded by the German Research Foundation ( KU 1194/8-1 , DE438/11-1 ; KR 1093/9-1 ; FOR2488 ), intramural funding of the Department of Neurology, Kiel University and the Thiemann foundation. The authors declare that there is no conflict of interest regarding the publication of this article. Franziska Hopfner received grants from the German Research Council (DFG) and the Thiemann foundation, Stefanie H. Müller, Silke Szymczak, Olaf Junge, Lukas Tittmann, Sandra May, Katja Lohmann, Harald Grallert, Wolfgang Lieb, Konstantin Strauch, Martina Müller-Nurasyid, Klaus Berger, Barbara Schormair, Juliane Winkelmann, Walter Maetzler, Meike Kasten Christine Klein, André Franke, Michael Krawczak and Astrid Dempfle report no disclosures. Daniela Berg is a member of the UCB advisory board and receives grants from Michael J. Fox Foundation, Janssen Pharmaceutica N.V., German Parkinson's Disease Association (dPV), BMWi, BMBF, Parkinson Fonds Deutschland gGmbH, UCB Pharma GmbH, TEVA Pharma GmbH, EU, Novartis Pharma GmbH, Lundbeck, and Damp foundation. Brit Mollenhauer has received honoraria for consultancy from Roche, Biogen, UCB and Sun Pharma Advanced research Company. Brit Mollenhauer is member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG) , EU (Horizon2020) , Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung and the Michael J. Fox Foundation for Parkinson's Research Günter Höglinger was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology ( EXC 2145 SyNergy – ID 390857198 ). Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2 Heisenberg Program, HO2402/18-1 MSAomics), the German Federal Ministry of Education and Research (BMBF, 01KU1403A EpiPD; 01EK1605A HitTau), the NOMIS foundation (FTLD project), the ParkinsonFonds Germany (Hypothesis-free compound screen, alpha-Synuclein fragments in PD) the EU/EFPIA/Innovative Medicines Initiative [ 2 ] Joint Undertaking (IMPRIND grant n° 116,060). Günter Höglinger received research support from Neuropore, GE Health; has ongoing research collaborations with Orion, Prothena; serves as a consultant for Abbvie, Alzprotect, Asceneuron, Biogen, Biohaven, Novartis, Sanofi, UCB; Günter Höglinger received honoraria for scientific presentations from Abbvie, Biogen, Roche, Teva, UCB, Zambon. Günter Höglinger holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068,734). Thomas Gasser serves on the editorial board of the Journal of Parkinson's Disease. He holds a patent re: KASPP (LRRK2) Gene, its Production and Use for the Detection and Treatment of Neurodegenerative Diseases. Prof. Gasser has received speaker's honoraria from UCB Pharma, Novartis, Teva and MedUpdate. He is Chairman of the Scientific Advisory Board of the “Joint Programming for Neurodegenerative Diseases” program, funded by the European Commission. He has received grant support from the German Research Foundation (DFG), the German Federal Ministry of Education and Research (BMBF), the European Commission, the Helmholtz Association and The Michael J. Fox Foundation. Claudia Trenkwalder is supported by the MJ Fox foundation and by EU Horizon 2010. She receives honoraria or consultation fees from UCB, Gruenenthal, Orion. Claudia Trenkwalder has received speaker's honoraria from Roche, and Britannia. Günther Deuschl has received lecture fees from UCB, Medtronic and Desitin and has been serving as a consultant for Medtronic, Sapiens, Boston Scientific and Britannica. He received royalties from Thieme publishers. He receives through his institution funding for his research from the German Research Council, the German Ministery of Education and Health and Medtronic. Gregor Kuhlenbäumer receives research support from the German Research Council (DFG) and the Christian-Albrechts-University Kiel. The Dortmund Health Study was supported by unrestricted grants to the University of Muenster from the German Migraine and Headache Society and a consortium formed with equal shares by Allmiral, Astra-Zeneca, Berlin-Chemie, Boehringer Ingelheim Pharma, Boots Healthcare, GlaxoSmithKline, Janssen Cilag, McNeil Pharmaceuticals, MSD Sharp & Dohme, Pfizer. No sponsor had access to the data nor participated in the writing of the manuscript.